Your session is about to expire
← Back to Search
Monoclonal Antibodies
Sotorasib + Panitumumab for Colorectal Cancer (CodeBreak300 Trial)
Phase 3
Waitlist Available
Research Sponsored by Amgen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Pathologically documented metastatic colorectal adenocarcinoma with Kirsten rat sarcoma (KRAS) p.G12C mutation as determined by prospective central testing, using the analytically validated Qiagen Therascreen KRAS RGQ polymerase chain reaction Kit in CRC as an investigational device demonstrating a KRAS p.G12C mutation is present. Local testing and documentation of KRAS p.G12C mutation should have been previously performed as part of standard of care.
- Estimated glomerular filtration rate based on Modification of Diet in Renal Disease (MDRD) calculation ≥30 mL/min/1.73 m^2.
Must not have
- Adequately treated urothelial papillary non-invasive carcinoma or carcinoma in situ.
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 3 years
Awards & highlights
No Placebo-Only Group
Pivotal Trial
Summary
This trial is testing two doses of sotorasib combined with panitumumab in patients with a specific type of colorectal cancer that has not responded to other treatments. Sotorasib targets a genetic mutation in the cancer cells, while panitumumab helps the immune system attack the cancer. The goal is to see if this combination can help patients live longer without their cancer getting worse.
Who is the study for?
Adults over 18 with metastatic colorectal cancer that has a specific mutation (KRAS p.G12C) can join this trial. They must have tried at least one other treatment and their cancer should be measurable by certain medical criteria. Good organ function and performance status are required, but those with severe skin, breast, or prostate conditions without current disease, brain metastases treated over 4 weeks ago without progression, or other cancers cured more than 3 years ago may also qualify.
What is being tested?
The study is testing the effectiveness of Sotorasib combined with Panitumumab against either Trifluridine/Tipiracil or Regorafenib in patients whose colorectal cancer has progressed after previous treatments. The main goal is to see which combination helps slow down the cancer's growth better.
What are the potential side effects?
Potential side effects include skin reactions from Panitumumab; liver enzyme changes from Sotorasib; fatigue and hand-foot syndrome from Regorafenib; and low blood counts leading to infections, fatigue, nausea from Trifluridine/Tipiracil.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My colorectal cancer has a specific KRAS mutation.
Select...
My kidney function, based on a specific test, is at an acceptable level.
Select...
My blood counts and organ functions are within the required ranges for the trial.
Select...
I am able to care for myself and perform daily activities.
Select...
I am 18 years old or older.
Select...
My colorectal cancer has a specific KRAS mutation.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My bladder cancer has been treated and is not invasive.
Select...
I had skin cancer (not melanoma) treated and currently show no signs of it.
Select...
My breast ductal carcinoma in situ has been treated and shows no signs of disease.
Select...
I do not have serious heart conditions like recent heart attacks or unstable heart rhythms.
Select...
I had cervical cancer that was treated and now shows no signs of the disease.
Select...
I have or had lung scarring or inflammation.
Select...
I have a prostate condition but no prostate cancer.
Select...
I have a severe stomach or intestine problem that affects my nutrition.
Select...
I have been treated with a KRAS G12C inhibitor before.
Select...
My cancer has spread to the lining of my brain and spinal cord.
Select...
I had blood cancer but have been free of it for over 2 years.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ approximately 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 3 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Average Score of Patient Global Impression of Change (PGIC)
Average Score on Single Question on Symptom Bother GP5 from Functional Assessment of Cancer Therapy - General (FACT-G)
Change from Baseline For All Subscales and Domains of EORTC QLQ-C30
+8 moreSide effects data
From 2022 Phase 1 trial • 20 Patients • NCT0488706414%
Constipation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Normal Hepatic Function
Moderate Hepatic Impairment
Severe Hepatic Impairment
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Arm B: Sotorasib 240 mg QD + panitumumabExperimental Treatment2 Interventions
Group II: Arm A: Sotorasib 960 mg QD + panitumumabExperimental Treatment2 Interventions
Group III: Arm C : Investigator's choiceActive Control2 Interventions
Participants will be administered trifluridine and tipiracil, or regorafenib
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Panitumumab
2017
Completed Phase 3
~7150
Sotorasib
2021
Completed Phase 1
~370
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Sotorasib targets the KRAS G12C mutation, inhibiting a key driver of cancer cell growth, while Panitumumab is an anti-EGFR monoclonal antibody that blocks signals promoting cell division and survival. These mechanisms are crucial for tailoring treatment to colorectal cancer patients' genetic profiles, ensuring more effective and personalized therapy.
Panitumumab: a summary of clinical development in colorectal cancer and future directions.
Panitumumab: a summary of clinical development in colorectal cancer and future directions.
Find a Location
Who is running the clinical trial?
AmgenLead Sponsor
1,466 Previous Clinical Trials
1,401,336 Total Patients Enrolled
MDStudy DirectorAmgen
1,003 Previous Clinical Trials
945,080 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My bladder cancer has been treated and is not invasive.I had skin cancer (not melanoma) treated and currently show no signs of it.My cancer was treated over 3 years ago, with no current signs of it and considered low risk for coming back.My breast ductal carcinoma in situ has been treated and shows no signs of disease.I had brain metastases treated and stable for over 4 weeks with no new growth.I do not have serious heart conditions like recent heart attacks or unstable heart rhythms.My cancer can be measured by scans and has grown after any radiation treatments.My colorectal cancer has a specific KRAS mutation.My kidney function, based on a specific test, is at an acceptable level.My blood and organ functions are within normal ranges as of two weeks ago.I've had at least one treatment for my cancer after it spread and it didn't work or my cancer came back.I had cervical cancer that was treated and now shows no signs of the disease.My blood counts and organ functions are within the required ranges for the trial.I have or had lung scarring or inflammation.I have had cancer other than my current one in the last 3 years.I have a prostate condition but no prostate cancer.I am able to care for myself and perform daily activities.I am 18 years old or older.I have a severe stomach or intestine problem that affects my nutrition.I have been treated with a KRAS G12C inhibitor before.My cancer has spread to the lining of my brain and spinal cord.My colorectal cancer has a specific KRAS mutation.I had blood cancer but have been free of it for over 2 years.
Research Study Groups:
This trial has the following groups:- Group 1: Arm A: Sotorasib 960 mg QD + panitumumab
- Group 2: Arm B: Sotorasib 240 mg QD + panitumumab
- Group 3: Arm C : Investigator's choice
Awards:
This trial has 2 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.